Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258998 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL6464207 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL8117010 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL60323 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| SCHEMBL8587285 | 1.00 | TDP1 (0.68) | TDP1ABCB1POLBMAPK1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL17061382 | 0.98 | TDP1 (0.66) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL60713 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL13893402 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL421756 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 | |
| SCHEMBL426635 | 0.95 | TDP1 (0.71) | TDP1ABCB1POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612172-B1 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LTD (IN) | 2025-04-09 | — | — | EP | disclosed |
| CN-117915786-A | Agent for heart disease and method for improving heart disease | 未来生物科学实验室株式会社 | 2024-04-19 | — | — | CN | disclosed |
| US-11680078-B2 | Anticancer compounds | GODAVARI BIOREFINERIES LTD. (IN) | 2023-06-20 | — | — | US | disclosed |
| US-20230132332-A1 | Green Methods of Carbohydrate Acetylation | UNITED STATES DEPARTMENT OF ENERGY | 2023-04-27 | — | — | US | disclosed |
| US-20220389046-A1 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LIMITED | 2022-12-08 | — | — | US | disclosed |
| US-11084843-B2 | Anticancer compounds | GODAVARI BIOREFINERIES LTD. (IN) | 2021-08-10 | — | — | US | disclosed |
| EP-3612172-A2 | ANTICANCER COMPOUNDS | Godavari Biorefineries Ltd. (IN) | 2020-02-26 | — | — | EP | disclosed |
| US-20190284222-A1 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LTD. (IN) | 2019-09-19 | — | — | US | disclosed |
| WO-2018193476-A2 | ANTICANCER COMPOUNDS | GODAVARI BIOREFINERIES LIMITED (IN) | 2018-10-25 | — | — | WO | disclosed |
| US-20140162900-A1 | METHOD FOR HIGH-THROUGHPUT SCREENING OF COMPOUNDS AND COMBINATIONS OF COMPOUNDS FOR DISCOVERY AND QUANTIFICATION OF ACTIONS, PARTICULARLY UNANTICIPATED THERAPEUTIC OR TOXIC ACTIONS, IN BIOLOGICAL SYSTEMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-06-12 | — | — | US | disclosed |
| EP-1687035-A1 | METHOD FOR HIGH-THROUGHPUT SCREENING OF COMPOUNDS AND COMBINATIONS OF COMPOUNDS FOR DISCOVERY AND QUANTIFICATION OF ACTIONS, PARTICULARLY UNANTICIPATED THERAPEUTIC OR TOXIC ACTIONS, IN BIOLOGICAL SYSTEMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1663319-A2 | METHODS FOR COMPARING RELATIVE FLUX RATES OF TWO OR MORE BIOLOGICAL MOLECULES IN VIVO THROUGH A SINGLE PROTOCOL | The Regents of the University of California (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050202406-A1 | Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-15 | — | — | US | disclosed |
| WO-2005051434-A1 | METHOD FOR HIGH-THROUGHPUT SCREENING OF COMPOUNDS AND COMBINATIONS OF COMPOUNDS FOR DISCOVERY AND QUANTIFICATION OF ACTIONS, PARTICULARLY UNANTICIPATED THERAPEUTIC OR TOXIC ACTIONS, IN BIOLOGICAL SYSTEMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005033652-A2 | METHODS FOR COMPARING RELATIVE FLUX RATES OF TWO OR MORE BIOLOGICAL MOLECULES IN VIVO THROUGH A SINGLE PROTOCOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005015155-A2 | METHODS FOR COMPARING RELATIVE FLUX RATES OF TWO OR MORE BIOLOGICAL MOLECULES IN VIVO THROUGH A SINGLE PROTOCOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005009597-A2 | METHODS FOR COMPARING RELATIVE FLUX RATES OF TWO OR MORE BIOLOGICAL MOLECULES IN VIVO THROUGH A SINGLE PROTOCOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050019251-A1 | Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-01-27 | — | — | US | disclosed |
| US-20030224420-A1 | Method for isolating and measuring proliferation of long-term label retaining cells and stem cells | CALIFORNIA UNIVERSITY OF THE REGENTS OF, THE | 2003-12-04 | — | — | US | disclosed |
| WO-2003087314-A2 | METHOD FOR ISOLATING AND MEASURING PROLIFERATION OF LONG-TERM LABEL RETAINING CELLS AND STEM CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284222-A1 | ANTICANCER COMPOUNDS | MKI67, CCNI, API5 | TDP1 2695/4885ABCB1 74/4885POLB 1690/4885 |
| US-20230132332-A1 | Green Methods of Carbohydrate Acetylation | PUF60, HDAC10, NAT10 | TDP1 2977/4885ABCB1 4305/4885POLB 2890/4885 |
| US-11680078-B2 | Anticancer compounds | MKI67, CCNI, API5 | TDP1 2695/4885ABCB1 74/4885POLB 1690/4885 |
| US-20050019251-A1 | Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol | FABP1, SLC35B2, SLC10A1 | TDP1 3588/4885ABCB1 1244/4885POLB 485/4885 |
| US-20220389046-A1 | ANTICANCER COMPOUNDS | MKI67, CCNI, API5 | TDP1 2695/4885ABCB1 74/4885POLB 1690/4885 |
| US-11084843-B2 | Anticancer compounds | MKI67, CCNI, API5 | TDP1 2695/4885ABCB1 74/4885POLB 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.